Sanofi, Protein Sciences win flu jab nods in older adults

A couple of flu vaccine makers have new patient populations to target, thanks to a pair of recent FDA approvals in older adults. On Monday, the agency gave Sanofi ($SNY) the thumbs up to include additional efficacy data in its prescribing information for Fluzone High-Dose that demonstrate improved protection against the standard Fluzone trivalent in adults age 65 and older. And late last week, Connecticut-based Protein Sciences said U.S. regulators had green-lighted its egg-free flu vaccine, Flublok, for use in people age 50 and older. Release | Release

Suggested Articles

The FDA is evaluating the possibility of prosecuting those involved in rogue herpes vaccine research led by a Southern Illinois University professor.

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

Experts say technology is advancing to develop vaccines faster at a time of increasing emerging disease outbreaks.